Horizon Therapeutics Public (NASDAQ:HZNP) Upgraded to “B-” by TheStreet

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.

Other equities research analysts have also issued research reports about the stock. HC Wainwright began coverage on shares of Horizon Therapeutics Public in a report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 target price for the company. StockNews.com raised shares of Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. SVB Leerink boosted their price target on shares of Horizon Therapeutics Public from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. BMO Capital Markets lowered their price target on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating on the stock in a research report on Thursday, August 4th. Finally, Morgan Stanley decreased their target price on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating on the stock in a research report on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.00.

Horizon Therapeutics Public Price Performance

Horizon Therapeutics Public stock opened at $77.53 on Tuesday. Horizon Therapeutics Public has a 52-week low of $57.84 and a 52-week high of $117.49. The firm has a market capitalization of $17.57 billion, a price-to-earnings ratio of 31.77, a PEG ratio of 1.54 and a beta of 1.09. The company has a fifty day simple moving average of $67.51 and a 200-day simple moving average of $74.32. The company has a quick ratio of 3.74, a current ratio of 3.96 and a debt-to-equity ratio of 0.51.

Institutional Trading of Horizon Therapeutics Public

Large investors have recently made changes to their positions in the company. CoreCap Advisors LLC purchased a new stake in shares of Horizon Therapeutics Public during the second quarter worth approximately $33,000. Allworth Financial LP increased its stake in shares of Horizon Therapeutics Public by 936.7% during the third quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 562 shares during the period. CI Investments Inc. increased its stake in shares of Horizon Therapeutics Public by 75.9% during the third quarter. CI Investments Inc. now owns 628 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 271 shares during the period. Tcwp LLC purchased a new stake in shares of Horizon Therapeutics Public during the first quarter worth approximately $41,000. Finally, Steward Financial Group LLC purchased a new stake in shares of Horizon Therapeutics Public during the second quarter worth approximately $41,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Featured Articles

Analyst Recommendations for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.